-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 25, Jimin Trust Group announced that its subsidiary Jiangsu Jiye Biopharmaceutical Co.
JYB1904 was independently developed by Shanghai Jiyu Pharmaceutical Technology Co.
, Ltd.
, a subsidiary of Jimin Trust.
It is a class 1 new drug of biological products with independent intellectual property rights.
The clinical trial application was accepted by CDE on January 14, 2022, and the clinical trial was obtained in only 70 days.
Implied License
.
IgE is the main immunoglobulin that mediates type I hypersensitivity disease.
When the body is exposed to allergens, the allergens can combine with IgE bound on the surface of effector cells FcεRI and cross-link each other to form cross-links, causing inflammatory mediators.
release, leading to various allergic symptoms [1 , 2 ] .
Jimin Trust researchers found that JYB1904 can specifically bind to free IgE, thereby blocking the binding of IgE to its receptor FcεRI, thereby preventing it from being activated by allergens, and is expected to rapidly and effectively relieve the symptoms of patients clinically .
In preclinical studies comparing head-to-head with omalizumab, JYB1904 showed better biological activity, druggability and stability, fast onset and good efficacy in animal asthma models, and good safety in animals.
Drug serum half-life is long [3 ] .
These findings indicate that JYB1904 injection has excellent clinical therapeutic potential and can provide a potential new solution for the clinical treatment of moderate to severe asthma and other allergic diseases .
At present, Jimin Trust has completed the domestic clinical research plan of JYB1904 in order to rapidly advance the clinical phase I trial .
Looking forward to the product's early release, bringing good news to patients .
About Shanghai Jiyu Pharmaceutical Technology Co.
, Ltd.
Shanghai Jiyu Pharmaceutical Technology Co.
, Ltd.
is a wholly-owned subsidiary of Jimin Trust Group.
It is committed to becoming a drug research and development center with global influence.
Its research and development pipeline covers biological macromolecular innovative drugs, chemical small molecule innovative drugs, innovative traditional Chinese medicine, complex Generic and high-end preparations are committed to making breakthroughs in the therapeutic fields of kidney disease, tumor, cardiovascular and cerebrovascular, respiratory system, anti-infection, pediatrics, pain,
etc.
The research and development of JYB1904 injection is led by the company's Macromolecular Innovative Drug Research Institute.
The institute has built a 70 billion-level Fijian fully human antibody library, and independently developed the Feitai antibody discovery platform.
Several antibody drugs have entered the market.
IND or IND filing preparation stage
.
At present, the new coronavirus neutralizing antibody JMB2002 independently developed by the hospital has completed Phase I clinical trials.
The latest research has confirmed that it has a good neutralizing function against the new coronavirus Omicron variant.
The relevant results have been published in Science
.
About Jimin Trusted Group Jimin Trusted Group was founded in 1999 and is headquartered in Nanchang, China.
Its main product pipelines are in five areas: kidney disease, tumor, cardiovascular and cerebrovascular, respiratory anti-infection, and pain.
It is committed to providing patients with high-quality medicines and innovative pharmaceutical solutions .
As one of the leading large-scale modern pharmaceutical groups in China, Jimin Trust Group has been ranked among the top 100 in China's pharmaceutical industry for many consecutive years .
For more information visit: References
1.
Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C.
Structural and Physical Basis for Anti-IgE Therapy.
Scientific reports.
2015; 5:11581.
2.
Palomares O, Akdis M, Martin-Fontecha M, Akdis CA.
Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells.
Immunological reviews.
2017; 278(1):219-36.
3.
Liu P, Pan Z, Gu C, Cao X.
Liu X, Zhang J, Xiao Z, Wang X, Guo H, Ju D, Deng SJ.
An omalizumab biobetter antibody with improved stability and efficacy for the treatment of allergic diseases.
Frontiers in Immunology.
2020; 11:1-15.
JYB1904 was independently developed by Shanghai Jiyu Pharmaceutical Technology Co.
, Ltd.
, a subsidiary of Jimin Trust.
It is a class 1 new drug of biological products with independent intellectual property rights.
The clinical trial application was accepted by CDE on January 14, 2022, and the clinical trial was obtained in only 70 days.
Implied License
.
IgE is the main immunoglobulin that mediates type I hypersensitivity disease.
When the body is exposed to allergens, the allergens can combine with IgE bound on the surface of effector cells FcεRI and cross-link each other to form cross-links, causing inflammatory mediators.
release, leading to various allergic symptoms [1 , 2 ] .
Jimin Trust researchers found that JYB1904 can specifically bind to free IgE, thereby blocking the binding of IgE to its receptor FcεRI, thereby preventing it from being activated by allergens, and is expected to rapidly and effectively relieve the symptoms of patients clinically .
In preclinical studies comparing head-to-head with omalizumab, JYB1904 showed better biological activity, druggability and stability, fast onset and good efficacy in animal asthma models, and good safety in animals.
Drug serum half-life is long [3 ] .
These findings indicate that JYB1904 injection has excellent clinical therapeutic potential and can provide a potential new solution for the clinical treatment of moderate to severe asthma and other allergic diseases .
At present, Jimin Trust has completed the domestic clinical research plan of JYB1904 in order to rapidly advance the clinical phase I trial .
Looking forward to the product's early release, bringing good news to patients .
About Shanghai Jiyu Pharmaceutical Technology Co.
, Ltd.
Shanghai Jiyu Pharmaceutical Technology Co.
, Ltd.
is a wholly-owned subsidiary of Jimin Trust Group.
It is committed to becoming a drug research and development center with global influence.
Its research and development pipeline covers biological macromolecular innovative drugs, chemical small molecule innovative drugs, innovative traditional Chinese medicine, complex Generic and high-end preparations are committed to making breakthroughs in the therapeutic fields of kidney disease, tumor, cardiovascular and cerebrovascular, respiratory system, anti-infection, pediatrics, pain,
etc.
The research and development of JYB1904 injection is led by the company's Macromolecular Innovative Drug Research Institute.
The institute has built a 70 billion-level Fijian fully human antibody library, and independently developed the Feitai antibody discovery platform.
Several antibody drugs have entered the market.
IND or IND filing preparation stage
.
At present, the new coronavirus neutralizing antibody JMB2002 independently developed by the hospital has completed Phase I clinical trials.
The latest research has confirmed that it has a good neutralizing function against the new coronavirus Omicron variant.
The relevant results have been published in Science
.
About Jimin Trusted Group Jimin Trusted Group was founded in 1999 and is headquartered in Nanchang, China.
Its main product pipelines are in five areas: kidney disease, tumor, cardiovascular and cerebrovascular, respiratory anti-infection, and pain.
It is committed to providing patients with high-quality medicines and innovative pharmaceutical solutions .
As one of the leading large-scale modern pharmaceutical groups in China, Jimin Trust Group has been ranked among the top 100 in China's pharmaceutical industry for many consecutive years .
For more information visit: References
1.
Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C.
Structural and Physical Basis for Anti-IgE Therapy.
Scientific reports.
2015; 5:11581.
2.
Palomares O, Akdis M, Martin-Fontecha M, Akdis CA.
Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells.
Immunological reviews.
2017; 278(1):219-36.
3.
Liu P, Pan Z, Gu C, Cao X.
Liu X, Zhang J, Xiao Z, Wang X, Guo H, Ju D, Deng SJ.
An omalizumab biobetter antibody with improved stability and efficacy for the treatment of allergic diseases.
Frontiers in Immunology.
2020; 11:1-15.
